No Data
Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
Crinetics Pharmaceuticals Analyst Ratings
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences